Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;8(1):53-8.

History of BCG Vaccine

Simona Luca  1 , Traian Mihaescu
Affiliations

History of BCG Vaccine

Simona Luca et al. Maedica (Bucur). 2013 Mar.

Abstract

Tuberculosis (TB) is still responsible for 2 million deaths every year despite being a treatable airborne infectious disease. "Consumption" and "Phthisis" were terms historically used to describe TB, which was responsible for one in four deaths in the 19th century. Due to its infectious nature, chronic progression and long treatment, TB is a great burden for society. Moreover the emergence of multi-drug resistant TB and the current TB-HIV epidemic has raised even greater concern. Treating and preventing TB has become a permanent challange since the ancient times. Bacille Calmette-Guérin (BCG) is the only vaccine available today and has been used for more than 90 years with astonishing safety records. However, its efficacy remains controversial. No universal BCG vaccination policy exists, with some countries merely recommending its use and others that have implemented immunization programs. In this article we review several important milestones of BCG vaccine development from the discovery till today.

Keywords: BCG; Tuberculosis; history; review; vaccine.

PubMed Disclaimer

References

    1. McShane H. Tuberculosis Vaccines: Beyond Bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci. 2011;366:2782–9. - PMC - PubMed
    1. Ottenhoff THM, Kaufmann SHE. Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? Chitnis CE, editor. PLoS Pathog. 2012;8:e1002607–12. - PMC - PubMed
    1. Ottenhoff THM. Overcoming the Global Crisis: "yes, we can," but also for TB ... ? Eur J Immunol. 2009;39:2014–20. - PubMed
    1. Kaufmann SHE, Winau F. From Bacteriology to Immunology: The Dualism of Specificity. Nat. Immunol. 2005;6:1063–6. - PubMed
    1. Kaufmann SH, Hussey G, Lambert P-H. New Vaccines for Tuberculosis. Lancet. 2010;375:2110–9. - PubMed

LinkOut - more resources